CRISPR Clinical Translation

Gene editing has crossed the threshold from laboratory research to clinical medicine. The pace of translation is accelerating: Casgevy (the first CRISPR therapy) was approved in late 2023 for Sickle Cell Disease and transfusion-dependent beta-thalassemia, and by mid-2026 the clinical pipeline spans 50+ CRISPR trials recruiting — yet Casgevy remains the only approved CRISPR therapy, underscoring how much of the field is still mid-trial.

The April 2026 inflection point: in vivo CRISPR cleared Phase 3 for the first time. Intellia Therapeutics reported positive topline Phase 3 results from the HAELO trial of lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) in hereditary angioedema — a global first for in vivo gene editing. A single 50 mg LNP infusion that inactivates the liver KLKB1 gene cut HAE attacks 87% vs placebo (p<0.0001); 62% of treated patients were entirely attack-free and therapy-free (vs 11% on placebo), with no serious adverse events in the lonvo-z arm. Intellia has begun a rolling BLA and targets a US launch in 1H 2027. Where Casgevy proved ex vivo CRISPR (cells edited outside the body), lonvo-z proves the harder in vivo path — editing the patient's own organ directly — at registrational scale. (Intellia HAELO Phase 3)

The most striking prior clinical result is the ANGPTL3 cholesterol trial at Cleveland Clinic. CTX310, a single-infusion CRISPR therapy delivered via lipid nanoparticles, targets the ANGPTL3 gene in liver cells. In 15 Phase 1 patients, the results were dramatic: LDL cholesterol dropped approximately 50% and triglycerides dropped approximately 55% within two weeks, with effects sustained for over 60 days. No serious adverse events were reported. This matters enormously because the alternative — lifelong statin medication — has a well-documented adherence problem (roughly 50% of patients stop taking statins within a year).

The one-time treatment paradigm is the transformative promise. Rather than managing chronic conditions with daily medication, gene editing offers the possibility of a single intervention that permanently corrects the underlying genetic cause. The Cleveland Clinic trial demonstrates this for cardiovascular disease (the leading cause of death globally), while Casgevy demonstrated it for Sickle Cell Disease. The ANGPTL3 trial used lipid nanoparticle delivery (intravenous infusion targeting the liver), avoiding the need for bone marrow extraction and stem cell transplantation that Casgevy requires.

Key Claims

• In vivo CRISPR clears Phase 3 (a global first) — Lonvo-z cut hereditary angioedema attacks 87% vs placebo (p<0.0001); mean monthly attacks 0.26 (lonvo-z) vs 2.10 (placebo); 62% attack-free vs 11%. Single 50 mg LNP infusion inactivating liver KLKB1, 80 patients. No serious adverse events in the treatment arm. Evidence: strong (Intellia HAELO Phase 3)
• Casgevy is still the only approved CRISPR therapy — Despite 50+ trials recruiting by mid-2026, the regulatory bar means most modalities remain mid-trial. Evidence: strong (multi-source) (Beam clinical 2026)
• LDL -50%, triglycerides -55% within 2 weeks — Single CRISPR infusion (CTX310) targeting ANGPTL3 in 15 Phase 1 patients. Effects sustained 60+ days. Evidence: strong (Cleveland Clinic Trial)
• No serious adverse events — Cleveland Clinic Phase 1 safety profile clean across 15 patients. Evidence: moderate (small sample) (Cleveland Clinic Trial)
• Base editing de-risked across 3 indications — AATD, familial hypercholesterolemia, and sickle cell, per Beam/Verve clinical readouts. Evidence: moderate (Beam clinical 2026)
• One-time treatment vs. lifelong medication — Gene editing addresses the root genetic cause rather than managing symptoms. 50% of statin patients stop within a year. Evidence: strong (Cleveland Clinic Trial)

Benchmarks & Data

• Casgevy: first (and as of mid-2026, only) approved CRISPR therapy (Dec 2023), Sickle Cell + beta-thalassemia
• Lonvo-z (Intellia, HAELO Phase 3): 87% attack reduction, p<0.0001, single 50 mg dose, 80 patients; rolling BLA 2H 2026, US launch target 1H 2027
• CTX310: LDL -50%, triglycerides -55%, sustained 60+ days, 15 patients
• Verve VERVE-102 (PCSK9 base editing): up to 69% LDL reduction, no serious AEs
• First FDA-approved prime editing trial: April 2024
• 50+ CRISPR trials recruiting by mid-2026 (was 19 base/prime editing trials in 5 countries as of Nov 2025)
• ANGPTL3 trial enrollment: June 2024 through August 2025

Open Questions

• How will the FDA frame the benefit/risk of a permanent, irreversible in vivo edit (lonvo-z) for a serious-but-non-fatal indication — and what precedent does its review set for the modality?
• Will the ANGPTL3 effect be truly permanent, or will liver cell turnover require re-dosing?
• Can lipid nanoparticle delivery achieve sufficient editing efficiency in Phase 2/3 at scale?
• What is the regulatory pathway for one-time gene therapies — how will pricing and reimbursement work?
• How will the 50+ recruiting base/prime/in-vivo trials perform compared to first-generation CRISPR-Cas9 approaches?
• What are the long-term (5+ year) safety profiles of in vivo gene editing?

Related Concepts

• Prime Editing — Next-gen search-and-replace editing in the clinical pipeline
• Base Editing — The "safer CRISPR" modality behind Beam, Verve, and much of the in vivo correction pipeline
• Epigenetic Editing — Safer alternative approach not yet in clinical trials
• Gene Therapy Delivery — Lipid nanoparticles enabling in vivo delivery

Backlinks

Pages that reference this concept:

• Intellia HAELO Phase 3
• Beam Base Editing Clinical 2026
• CRISPR Cholesterol Trial
• Prime Editing Suppressor tRNAs

Changelog

• 2026-06-24 — Added the Intellia HAELO Phase 3 milestone (first in vivo CRISPR to clear Phase 3; lonvo-z 87% attack reduction, rolling BLA, 1H 2027 launch). Updated trial count 19 → 50+ recruiting and clarified Casgevy remains the only approved CRISPR therapy. Added base-editing de-risking (Beam/Verve). Promoted frontier_status active → breakthrough.
• 2026-04-09 — Initial compilation from the Cleveland Clinic ANGPTL3 trial and prime-editing suppressor tRNA paper.